文献速递其他结缔组织病

干燥综合征的健康相关生活质量与成本

Health-related quality of life and costs in Sjögren's syndrome.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

本文综述干燥综合征(SS)患者的健康相关生活质量(HRQoL)、经济成本和工作能力障碍。多项跨国研究显示SS患者HRQoL较健康对照显著降低,降低程度与类风湿关节炎、系统性红斑狼疮、纤维肌痛及非SS干燥综合征相似。至今无治疗在足够效能的双盲安慰剂对照随机试验中显示改善HRQoL,但相关成本和工作能力障碍显著。

要点

  • SS患者HRQoL较健康对照显著降低,程度与RA、SLE、FM及非SS干燥综合征相似。
  • HRQoL受损与疲劳、疼痛/关节受累、眼干口干、瘙痒、性功能障碍、睡眠障碍、肺部表现、心理功能障碍及躯体功能受损相关。
  • 至今无治疗在足够效能的随机双盲安慰剂对照试验中显示改善HRQoL,但成本和工作能力障碍显著。

核心结论

  • 干燥综合征患者HRQoL显著降低且相关成本和工作能力障碍显著,亟需开发新的治疗策略。

研究设计与样本

  • 本文为文献综述,旨在概述干燥综合征的HRQoL、成本和工作能力障碍。

主要发现

  • 多项跨国研究显示SS患者HRQoL较健康对照显著降低,降低程度与RA、SLE、FM及非SS干燥综合征相似。
  • HRQoL受损与疲劳、疼痛/关节受累、眼干口干、瘙痒、性功能障碍、睡眠障碍、肺部表现、心理功能障碍及躯体功能受损相关。
  • 至今无治疗在足够效能的随机双盲安慰剂对照试验中显示改善HRQoL。
  • 原发性SS通常不损害预期寿命,但相关成本和工作能力障碍显著。

临床怎么用

  • 临床应关注SS患者HRQoL的多维度受损因素,包括疲劳、疼痛、眼干口干、瘙痒、性功能、睡眠、肺部表现及心理功能。
  • 对于无系统受累的SS患者,不应仅视为良性 nuisance 疾病,需重视其成本和工作能力障碍。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Health-related quality of life (HRQoL) has an increasing role in medical decision-making. This review of the literature aims to provide an overview on HRQoL, costs, and work disability in SS, a disease characterized by focal lymphocytic infiltration of exocrine glands with no therapeutics of proven immunomodulatory potential. HRQoL is markedly reduced in SS in multiple studies across many countries when compared with HRQoL in healthy controls. The reduction in HRQoL is similar to that observed in other chronic diseases such as RA, SLE, FM and, interestingly, non-SS sicca syndrome. Impaired HRQoL in SS has been found to be associated with fatigue, pain/articular involvement, ocular and oral involvement, pruritus, sexual dysfunction, impaired sleep, pulmonary manifestations, psychological dysfunction and impaired physical function. Until now, no therapeutic has been shown to improve HRQoL in an adequately powered double-blind, placebo-controlled randomized controlled trial. Although primary SS does not, in general, impair life expectancy and is often inappropriately considered a benign 'nuisanvce' disease for those patients without systemic manifestations, the associated costs and work disability are striking. This, together with the significant reduction in HRQoL, strongly argues for the development of new therapeutic approaches to manage this neglected disease.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Miyamoto ST, Valim V, Fisher BA, et al. Health-related quality of life and costs in Sjögren's syndrome. Rheumatology (Oxford). 2021. PMID: 30770918. doi:10.1093/rheumatology/key370

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。